These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Emerson MV; Lauer AK; Flaxel CJ; Wilson DJ; Francis PJ; Stout JT; Emerson GG; Schlesinger TK; Nolte SK; Klein ML Retina; 2007; 27(4):439-44. PubMed ID: 17420695 [TBL] [Abstract][Full Text] [Related]
25. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A Retina; 2007; 27(4):432-8. PubMed ID: 17420694 [TBL] [Abstract][Full Text] [Related]
26. A very effective treatment for neovascular macular degeneration. Stone EM N Engl J Med; 2006 Oct; 355(14):1493-5. PubMed ID: 17021326 [No Abstract] [Full Text] [Related]
27. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results. Leydolt C; Michels S; Prager F; Garhoefer G; Georgopoulos M; Polak K; Schmidt-Erfurth U Acta Ophthalmol; 2010 Aug; 88(5):594-600. PubMed ID: 19485959 [TBL] [Abstract][Full Text] [Related]
28. Anti-VEGF therapy: riding the wave of change. Hunyor AP Clin Exp Ophthalmol; 2008 Jul; 36(5):401-2. PubMed ID: 18925912 [No Abstract] [Full Text] [Related]
29. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage. Stifter E; Michels S; Prager F; Georgopoulos M; Polak K; Hirn C; Schmidt-Erfurth U Am J Ophthalmol; 2007 Dec; 144(6):886-892. PubMed ID: 17916314 [TBL] [Abstract][Full Text] [Related]
30. Avastin in myopic choroidal neovascularisation: is age the limit? Wong D; Li KK Br J Ophthalmol; 2008 Aug; 92(8):1011-2. PubMed ID: 18653589 [No Abstract] [Full Text] [Related]
31. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Costa RA; Jorge R; Calucci D; Cardillo JA; Melo LA; Scott IU Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4569-78. PubMed ID: 17003454 [TBL] [Abstract][Full Text] [Related]